Salspera is focused on developing an innovative technology platform designed to enhance the safe and effective delivery of immunotherapies specifically within solid tumors. The company has created proprietary therapeutic constructs that function as smart, guided micro-factories. These constructs are capable of producing highly potent immunotherapies directly within the tumor microenvironment, including both primary tumors and metastases. This approach aims to improve the efficacy of treatments while maintaining exceptional safety profiles, addressing a critical need in cancer therapy.

The therapeutic strategies employed by Salspera leverage various mechanisms of action to optimize the immune response against solid tumors. By utilizing their advanced platform, Salspera aims to revolutionize the treatment landscape for cancer patients, particularly those with challenging solid tumors. The combination of targeted delivery and localized production of immunotherapies represents a significant advancement in the field, potentially leading to improved patient outcomes and reduced side effects associated with traditional cancer treatments.

United States

Salspera is a clinical-stage biotechnology company committed to developing novel therapies for solid tumor cancers.  The company has a platform of microbial immunotherapies that have the potential to address a range of solid tumor cancers where unmet medical need is high.  We believe microbial immunotherapies could be used to create a new category of medicines with significant potential to improve the lives of patients.

Salspera

Company Details